van der Graaf W T, de Vries E G, Timmer-Bosscha H, Meersma G J, Mesander G, Vellenga E, Mulder N H
Division of Medical Oncology, University Hospital, Groningen, The Netherlands.
Cancer Res. 1994 Oct 15;54(20):5368-73.
The multidrug resistance (MDR) modulators amiodarone (AM), cyclosporin A (CsA), and PSC 833 were tested for their potential to modulate cytotoxicity of doxorubicin (DOX), vincristine (VCR), and mitoxantrone (MX) in a sensitive human small cell lung carcinoma cell line GLC4, in its DOX-resistant non-P-glycoprotein subline GLC4-Adr, and in its cisplatin-resistant subline GLC4-CDDP. GLC4-Adr, in which overexpression of the so-called multidrug resistance-associated protein has been demonstrated, is 91-fold resistant for DOX, 22-fold for VCR, and 7.5-fold for MX, compared with its sensitive cell line. AM previously modulated DOX and VCR resistance in the P-glycoprotein-positive human colon cancer cell line COLO 320. Cytotoxicity was studied in the microtiter well tetrazolium assay. In the small cell lung carcinoma cell lines described above, AM did not increase cytotoxicity of DOX, but increased VCR cytotoxicity; moreover, AM was shown to be a potent modulator of MX cytotoxicity. CsA did not potentiate DOX cytotoxicity, but, at a concentration of 4 microM, it modestly increased VCR cytotoxicity in GLC4. However, 0.8 and 4.0 microM CsA protected against MX cytotoxicity in GLC4 and GLC4-CDDP, but no effect was observed in GLC4-Adr. At the much higher ID10 concentration CsA modulated MX cytotoxicity 1.6-fold in GLC4-Adr and slightly in GLC4 and GLC4-CDDP. PSC 833, a nonimmunosuppressive CsA analogue, did not alter the cytotoxicity of DOX or MX in these cell lines, but potentiated VCR cytotoxicity in GLC4-Adr at a concentration of 0.4 microM. The modulation of MX cytotoxicity by AM and the protection by CsA was confirmed in a clonogenic assay. In the colony-forming unit granulocyte-monocyte assay, no additional MX toxicity on normal bone marrow by AM was observed. Flow cytometry of cellular MX fluorescence was performed in order to elucidate the mechanism behind the AM-induced increased MX cytotoxicity. This revealed an increase in cellular MX after 1-h incubation of MX combined with AM and an inhibition of efflux from GLC4 and GLC4-Adr; CsA and PSC 833 had no effect on MX efflux. An increase in MX-induced cleavable complexes by AM in GLC4 was observed using the K+/sodium dodecyl sulfate coprecipitation assay, but no effect of CsA was found. In conclusion, AM enhances MX and VCR cytotoxicity in these sensitive, non-P-glycoprotein DOX and cisplatin-resistant small cell lung carcinoma cell lines. It also inhibits efflux of MX and causes more MX-induced cleavable complexes.
对多药耐药(MDR)调节剂胺碘酮(AM)、环孢素A(CsA)和PSC 833进行了测试,以评估它们在人小细胞肺癌敏感细胞系GLC4、其对阿霉素(DOX)耐药的非P-糖蛋白亚系GLC4-Adr及其对顺铂耐药的亚系GLC4-CDDP中调节阿霉素(DOX)、长春新碱(VCR)和米托蒽醌(MX)细胞毒性的潜力。已证实在GLC4-Adr中所谓的多药耐药相关蛋白过表达,与敏感细胞系相比,其对DOX的耐药性高91倍,对VCR的耐药性高22倍,对MX的耐药性高7.5倍。AM先前已调节P-糖蛋白阳性的人结肠癌细胞系COLO 320中DOX和VCR的耐药性。采用微量滴定板四氮唑法研究细胞毒性。在上述小细胞肺癌细胞系中,AM未增加DOX的细胞毒性,但增加了VCR的细胞毒性;此外,AM被证明是MX细胞毒性的有效调节剂。CsA未增强DOX的细胞毒性,但在浓度为4μM时,它适度增加了GLC4中VCR的细胞毒性。然而,0.8μM和4.0μM的CsA可保护GLC4和GLC4-CDDP免受MX的细胞毒性,但在GLC4-Adr中未观察到效果。在高得多的ID10浓度下,CsA在GLC4-Adr中调节MX细胞毒性1.6倍,在GLC4和GLC4-CDDP中调节作用轻微。PSC 833是一种非免疫抑制性CsA类似物,在这些细胞系中未改变DOX或MX的细胞毒性,但在浓度为0.4μM时增强了GLC4-Adr中VCR的细胞毒性。在克隆形成试验中证实了AM对MX细胞毒性的调节作用以及CsA的保护作用。在集落形成单位粒细胞-单核细胞试验中,未观察到AM对正常骨髓有额外的MX毒性。进行细胞MX荧光的流式细胞术以阐明AM诱导的MX细胞毒性增加背后的机制。这表明MX与AM孵育1小时后细胞内MX增加,并且抑制了从GLC4和GLC4-Adr中的流出;CsA和PSC 833对MX流出没有影响。使用K⁺/十二烷基硫酸钠共沉淀试验观察到AM在GLC4中增加了MX诱导的可裂解复合物,但未发现CsA有作用。总之,AM增强了这些敏感的、非P-糖蛋白DOX和顺铂耐药的小细胞肺癌细胞系中MX和VCR的细胞毒性。它还抑制MX的流出并导致更多MX诱导的可裂解复合物。